IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
General Research Collaborations
Company/Organization Date Area of
Collaboration
Terms of Agreement
Alnylam 2008 RNAi Non-exclusive licensing deal for access to
Alynlam RNA interference technology in
oncology and metabolic disease signed in
May. Deal valued at $1bn comprising
$100m upfront in cash, $50m in
near-term technology transfer payments
($20m received in October 2008) and up
to $1bn in development/commercial
milestones and royalties ($171m per
product). Over 5 years, Takeda becomes
Alnylam’s strategic partner for RNAi
therapeutics. Takeda is granted the right
of first negotiation to develop and
commercialize Alnylam RNAi therapeutic
programs for the Asian market (excluding
Alnylam’s ALN-RSV01), while Alnylam can
opt-in to codevelop/commercialize
Takeda’s RNAi programs in the US.
Harvard University 2008 Oncology research Millennium signed an agreement to
investigate pathways that regulate cellular
protein homeostasis using a technology
developed by researchers at Harvard
University. These pathways are linked to
the pathogenic properties of a range of
cancers. Financial terms not disclosed
Faust Pharmaceuticals
(now Domain
Therapeutics)
2008 Drug discovery Research agreement with Takeda, under
which Faust Pharmaceuticals is to use the
NEUROCLID technology platform to
identify drug candidates targeting
undisclosed G-Protein Coupled Receptors
(GPCR) for Takeda. Financial terms not
disclosed.
Chemizon 2008 Drug discovery Expansion to previous collaboration using
Chemizon’s Discovery Platform.
Curidium Medica (UK) 2007 Depression drug
discovery
© 2009 IMS Health In cor po rated or its af fil i ates Page 99
Investment by Takeda Research
Investment (TRI) in Curidium Medica
(around 1.8%, totaling STG1.2m) in a
deal giving access to biomarkers and drug
targets related to depression identified
from Curidium’s research.